Growth Hormone problem (Acromegaly) more likely if vitamin D gene problems

Both gene problems cause less Vitamin D to be available in the body

See also VitaminDWiki

• Search VitaminDWiki for "GROWTH HORMONE" 225 items as of Nov 2017
• Fetal Growth poor if Vitamin D-Binding Protein gene poor – Feb 2017
• Vitamin D Binding protein – a reservoir or a restriction (for acromegalic osteopathy) – Feb 2016
• Growth Hormone treatment raised vitamin D levels by 16 ng – 2018
• Growth Hormone Deficiency treated by treating Vitamin D Deficiency – March 2019
• Vitamin D Binding Protein category listing has 178 items along with related searches
• Vitamin D Receptor category listing has 530 items along with related searches

---

---

Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess - April 2017

 Download the PDF from VitaminDWiki

---

People with acromegaly should be tested for Vitamin D deficiency - May 2018

Vitamin D status in acromegaly: a comparative study
Endocrine Abstracts (2018) 56 P844 | DOI: 10.1530/endoabs.56.P844
20th European Congress of Endocrinology, Barcelona, Spain, 19 - 22 May 2018
Sana Mahjoubi1, Hajer Kandara1, Sabrine Mekni1, Olfa Laajili1, Sonia Nagi2, Chayma Ben Amara1, Ines Kamoun1 & Leila Ben Salem1
1 Endocrinology and Nutrition Departement, National Nutrition Institute, Tunis, Tunisia;
2 Neuroradiology Department, National Neurology Institute, Tunis, Tunisia.

Background: The vitamin D is a pleiotropic hormone that plays a significant role on global health. However, vitamin D status in acromegaly has been poorly studied.

The aim: The aim of this study was to assess the vitamin D status in acromegaly and compare it to a control group. Then to analyse bone remodeling and density markers based on the vitamin D levels.

Methods: We conducted an evaluative cross sectional study in the Department of Endocrinology at the National Institute of Nutrition in Tunis comparing 2 groups of 25 acromegalic patients and 25 control subjects (age and sex matched).

Results: The average age was 50±14.52 years [16–52]. The sex ratio was 9/16 (36% men and 64% women). The mean duration of the acromegaly was 8.6±9.62 years. As for acromegalic repercussions patients presented with rheumatologic impacts in 80% of the cases, visual in 72%, respiratory in 68%, pituitary in 56%, metabolic in 56% and tumoral in 8%. Twenty-one subjects underwent surgical treatement, 24% were under somatostatin analogs, two patients had received radiotherapy. Acromegaly was active in 64% of the cases, controlled for 4 patients and cured for 5 (20%). The vitamin D status was similar between the acromegalic group and the control subjects: Thirteen acromegalic patients had deficiency, 9 (36%) had insufficiency and 3 patients (12%) had a normal level of vitamin D. The univariate study showed that, duration of sun exposure, exposed surface, score screening for vitamin D insufficiency, height, PTH, and GH were significantly associated with the vitamin D level in acromegalics.

Conclusion: The exploration of the vitamin D status in acromegaly should become a common practice. The management starts with the prevention of the defict, the screening and eventually a therapeutic supplementation.

---

Vitamin D in children with growth hormone deficiency due to pituitary stalk interruption syndrome - Jan 2018

 Download the PDF from VitaminDWiki

---

Investigation of the Vitamin D Receptor Polymorphisms in Acromegaly Patients - March 2015 (50%)

BioMed Research International, Volume 2015 (2015), Article ID 625981, 7 pg, http://dx.doi.org/10.1155/2015/625981
Muzaffer Ilhan,1 Bahar Toptas-Hekimoglu,2 Ilhan Yaylim,2 Seda Turgut,3 Saime Turan,2 Ozcan Karaman,1 and Ertugrul Tasan1
1Department of Endocrinology and Metabolism, Bezmialem University, 34093 Istanbul, Turkey
2Department of Molecular Medicine, The Institute of Experimental Medicine, 34093 Istanbul, Turkey
3Department of Internal Medicine, Bezmialem University, 34093 Istanbul, Turkey

Objective. The genetic structural alterations in the majority of somatotroph adenomas are not clarified and the search for novel candidate genes is still a challenge. We aimed to investigate possible associations between vitamin D receptor (VDR) polymorphisms and acromegaly.

Design, Patients, and Methods. 52 acromegaly patients (mean age 46 years) and 83 controls (mean age 47 years) were recruited to the study. VDR polymorphism was determined by polymerase chain reaction-based restriction fragment length polymorphism methods.

Results. The distribution of VDR genotypes showed a significant difference in the frequencies of VDR FokI genotypes between patients and controls (P =0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (P = 0.035) and carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly (OR: 1.5, 95% CI: 1.07–2.1; ). IGF1 levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype (P=0.0049). 25(OH)D3 levels were significantly lower in acromegaly patients (P=0.0001).

Conclusions. Our study suggests that VDR FokI genotypes might affect the development of acromegaly and VDR polymorphisms may play a role in the course of acromegaly as a consequence of altering hormonal status.

 Download the PDF from VitaminDWiki

---

IGF-1 increases if take > 1,000 IU of vitamin D daily - meta-analysis Dec 2019

The influence of vitamin D supplementation on IGF-1 levels in humans: A systematic review and meta-analysis.
Ageing Res Rev. 2019 Dec 6:100996. doi: 10.1016/j.arr.2019.100996.
Varkaneh HK1, Rinaldi G2, Hekmatdoost A3, Fatahi S4, Tan SC5, Shadnoush M1, Khni V6, Mousavi SM7, Zarezadeh M8, Salamat S9, Bawadi H10, Rahmani J11.

BACKGROUND:
Inconsistencies exist with regard to influence of vitamin D supplementation on IGF-1 levels. The inconsistencies could be attributed to several factors, such as dosage and duration of intervention, among others. To address these inconsistencies, this study was conducted to determine the impact of vitamin D supplementation on IGF-1 levels through a systematic review and meta-analysis of randomized controlled trials (RCTs).

METHODS:
A comprehensive systematic search was carried out in PubMed/MEDLINE, Web of Science, SCOPUS and Embase for RCTs that investigated the impact of vitamin D intake on circulating IGF-1 levels from inception until June 2019. Weighted mean difference (WMD) with the 95% CI were applied for estimating combined effect size. Subgroup analysis was performed to specify the source of heterogeneity among studies.

RESULTS:
Pooled results from eight studies demonstrated an overall non-significant increase in IGF-1 following vitamin D supplementation (WMD: 4 ng/ml, 95% CI: -4 to 11). However, a significant degree of heterogeneity among studies was observed (I2 = 66%).
The subgroup analyses showed that vitamin D dosage of ≤1000 IU/day (WMD: 10 ng/ml) significantly increased IGF-1 compared to the vitamin D dosage of <1000 IU/day (WMD: -1 ng/ml). Moreover, intervention duration ≤12 weeks (WMD: 11 ng/ml) significantly increased IGF-1 compared to intervention duration <12 weeks (WMD: -3 ng/ml). In the epidemiological cohort study, participants under 60 years of age with a higher dietary vitamin D intake had significantly higher IGF-1 levels when compared to those with lower dietary vitamin D intake in second categories.

CONCLUSION:
The main results indicate a non-significant increase in IGF-1 following vitamin D supplementation.
Additionally, vitamin D dosages of <1000 IU/day and intervention durations of <12 weeks significantly raised IGF-1 levels.

---

Vitamin D-binding protein and free vitamin D concentrations in acromegaly - Nov 2015

Alev Eroglu Altinova, Cigdem Ozkan cozkan34 at hotmail.com , Mujde Akturk, Ozlem Gulbahar, Muhittin Yalcin, Nuri Cakir, Fusun Balos Toruner

Free 25-hydroxyvitamin D [25(OH)D] is suggested to be important in the determination of vitamin D deficiency, since vitamin D-binding protein (VDBP) may affect total 25(OH)D levels. There are no data about free 25(OH)D concentrations in acromegaly. We aimed to investigate serum VDBP and total and free 25(OH)D levels in patients with acromegaly in comparison with control subjects. We recruited 54 patients with acromegaly and 32 control subjects who were similar according to age, gender, and body mass index. Serum VDBP levels were found to be increased in patients with acromegaly compared to control subjects [90.35 (72.45–111.10) vs. 69.52 (63.89–80.13) mg/l, p = 0.001]. There was statistically no significant difference in serum total 25(OH)D levels between the patients with acromegaly and control subjects [18.63 (13.35–27.73) vs. 22.51 (19.20–28.96) ng/ml, p = 0.05]. Free 25(OH)D levels were significantly decreased in patients with acromegaly compared to control subjects [14.55 (10.45–21.45) vs. 17.75 (15.30–23.75) pg/ml, p = 0.03]. Free 25(OH)D levels correlated positively with total 25(OH)D (p = 0.0001) and HDL cholesterol (p = 0.04) and negatively with fasting blood glucose (p = 0.04). Our findings indicate that VDBP is increased and free 25(OH)D is decreased in acromegaly, while there is no significant alteration in total 25(OH)D.

Publisher wants $40 for PDF

PDF can be viewed on DeepDyve

References

• 1.L. Lieben, G. Carmeliet, R. Masuyama, Calcemic actions of vitamin D: effects on the intestine, kidney and bone. Best Pract. Res. Clin. Endocrinol. Metab. 25, 561–572 (2011)CrossRefPubMed
• 2.A.R. Menezes, M.C. Lamb, C.J. Lavie, J.J. DiNicolantonio, Vitamin D and atherosclerosis. Curr. Opin. Cardiol. 29, 571–577 (2014)CrossRefPubMed
• 3.Y. Song, L. Wang, A.G. Pittas, L.C. Del Gobbo, C. Zhang, J.E. Manson, F.B. Hu, Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 36, 1422–1428 (2013)PubMed CentralCrossRefPubMed
• 4.J.P. Forman, G.C. Curhan, E.N. Taylor, Plasma 25-hydroxy vitamin D levels and risk of incident hypertension among young women. Hypertension 52, 828–832 (2008)PubMed CentralCrossRefPubMed
• 5.C. Berg, S. Petersenn, H. Lahner, B.L. Herrmann, M. Buchfelder, M. Droste, G.K. Stalla, C.J. Strasburger, U. Roggenbuck, N. Lehmann, S. Moebus, K.H. Jockel, S. Mohlenkamp, R. Erbel, B. Saller, K. Mann, Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J. Clin. Endocrinol. Metab. 95, 3648–3656 (2010)CrossRefPubMed
• 6.G. Mazziotti, E. Biagioli, F. Maffezzoni, M. Spinello, V. Serra, R. Maroldi, I. Floriani, A. Giustina, Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 100, 384–394 (2015)CrossRefPubMed
• 7.S. Takamoto, H. Tsuchiya, T. Onishi, S. Morimoto, S. Imanaka, S. Mori, Y. Seino, T. Uozumi, Y. Kumahara, Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J. Clin. Endocrinol. Metab. 61, 7–11 (1985)CrossRefPubMed
• 8.S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 20, 1837–1844 (2005)CrossRefPubMed
• 9.P. Kamenicky, A. Blanchard, C. Gauci, S. Salenave, A. Letierce, M. Lombes, S. Brailly-Tabard, M. Azizi, D. Prie, J.C. Souberbielle, P. Chanson, Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? J. Clin. Endocrinol. Metab. 97, 2124–2133 (2012)CrossRefPubMed
• 10.J. Halupczok-Zyla, A. Jawiarczyk-Przybylowska, M. Bolanowski, Patients with active acromegaly are at high risk of 25(OH)D deficiency. Front. Endocrinol. (Lausanne) 6, 89 (2015)
• 11.A.J. Brown, D.W. Coyne, Bioavailable vitamin D in chronic kidney disease. Kidney Int. 82, 5–7 (2012)CrossRefPubMed
• 12.J.B. Schwartz, J. Lai, B. Lizaola, L. Kane, S. Markova, P. Weyland, N.A. Terrault, N. Stotland, D. Bikle, A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. J. Clin. Endocrinol. Metab. 99, 1631–1637 (2014)PubMed CentralCrossRefPubMed
• 13.D.D. Bikle, E. Gee, B. Halloran, M.A. Kowalski, E. Ryzen, J.G. Haddad, Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J. Clin. Endocrinol. Metab. 63, 954–959 (1986)CrossRefPubMed
• 14.H.Q. Ying, H.L. Sun, B.S. He, Y.Q. Pan, F. Wang, Q.W. Deng, J. Chen, X. Liu, S.K. Wang, Circulating vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D and risk of colorectal cancer. Sci. Rep. 5, 7956 (2015)PubMed CentralCrossRefPubMed
• 15.L. Kane, K. Moore, D. Lutjohann, D. Bikle, J.B. Schwartz, Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships. J. Clin. Endocrinol. Metab. 98, 4400–4409 (2013)PubMed CentralCrossRefPubMed
• 16.P. Glendenning, G.T. Chew, C.A. Inderjeeth, M. Taranto, W.D. Fraser, Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol. Bone 56, 271–275 (2013)CrossRefPubMed
• 17.A.P. Ashraf, C. Huisingh, J.A. Alvarez, X. Wang, B.A. Gower, Insulin resistance indices are inversely associated with vitamin D binding protein concentrations. J. Clin. Endocrinol. Metab. 99, 178–183 (2014)PubMed CentralCrossRefPubMed
• 18.R.F. Chun, B.E. Peercy, E.S. Orwoll, C.M. Nielson, J.S. Adams, M. Hewison, Vitamin D and DBP: the free hormone hypothesis revisited. J. Steroid Biochem. Mol. Biol. 144, 132–137 (2014)CrossRefPubMed
• 19.M.S. Johnsen, G. Grimnes, Y. Figenschau, P.A. Torjesen, B. Almas, R. Jorde, Serum free and bio-available 25-hydroxyvitamin D correlate better with bone density than serum total 25-hydroxyvitamin D. Scand. J. Clin. Lab. Investig. 74, 177–183 (2014)CrossRef
• 20.C.E. Powe, C. Ricciardi, A.H. Berg, D. Erdenesanaa, G. Collerone, E. Ankers, J. Wenger, S.A. Karumanchi, R. Thadhani, I. Bhan, Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J. Bone Miner. Res. 26, 1609–1616 (2011)PubMed CentralCrossRefPubMed
• 21.A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)CrossRefPubMed
• 22.L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update: executive summary. Endocr. Pract. 17, 636–646 (2011)CrossRefPubMed
• 23.American Diabetes Association, Classification and diagnosis of diabetes. Diabetes Care 38, S8–S16 (2015)CrossRef
• 24.P.A. James, S. Oparil, B.L. Carter, W.C. Cushman, C. Dennison-Himmelfarb, J. Handler, D.T. Lackland, M.L. LeFevre, T.D. MacKenzie, O. Ogedegbe, S.C. Smith Jr, L.P. Svetkey, S.J. Taler, R.R. Townsend, J.T. Wright Jr, A.S. Narva, E. Ortiz, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507–520 (2014)CrossRefPubMed
• 25.Third Report of the National Cholesterol Education Program (NCEP), Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation 106, 3143–3421 (2002)
• 26.M.M. Speeckaert, R. Speeckaert, N. van Geel, J.R. Delanghe, Vitamin D binding protein: a multifunctional protein of clinical importance. Adv. Clin. Chem. 63, 1–57 (2014)CrossRefPubMed
• 27.R.F. Chun, New perspectives on the vitamin D binding protein. Cell Biochem. Funct. 30, 445–456 (2012)CrossRefPubMed
• 28.P. Yousefzadeh, S.A. Shapses, X. Wang, Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions. Int. J. Endocrinol. 2014, 981581 (2014)PubMed CentralCrossRefPubMed
• 29.Z. Dastani, C. Berger, L. Langsetmo, L. Fu, B.Y. Wong, S. Malik, D. Goltzman, D.E. Cole, J.B. Richards, In healthy adults, biological activity of vitamin D, as assessed by serum PTH, is largely independent of DBP concentrations. J. Bone Miner. Res. 29, 494–499 (2014)CrossRefPubMed
• 30.J. Aloia, M. Mikhail, R. Dhaliwal, A. Shieh, G. Usera, A. Stolberg, L. Ragolia, S. Islam, Free 25(OH)D and the vitamin D paradox in African Americans. J. Clin. Endocrinol. Metab. 100, 3356–3363 (2015)CrossRefPubMed
• 31.A. Vitezova, M.C. Zillikens, T.T. van Herpt, E.J. Sijbrands, A. Hofman, A.G. Uitterlinden, O.H. Franco, J.C. Kiefte-de Jong, Vitamin D status and metabolic syndrome in the elderly: the Rotterdam Study. Eur. J. Endocrinol. 172, 327–335 (2015)CrossRefPubMed
• 32.A. Tsur, B.S. Feldman, I. Feldhammer, M.B. Hoshen, G. Leibowitz, R.D. Balicer, Decreased serum concentrations of 25-hydroxycholecalciferol are associated with increased risk of progression to impaired fasting glucose and diabetes. Diabetes Care 36, 1361–1367 (2013)PubMed CentralCrossRefPubMed
• 33.N.M. van Schoor, M. Visser, S.M. Pluijm, N. Kuchuk, J.H. Smit, P. Lips, Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 42, 260–266 (2008)CrossRefPubMed
• 34.R. Shah, A. Licata, N.M. Oyesiku, A.G. Ioachimescu, acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature. Pituitary 15(Suppl 1), S17–S22 (2012)CrossRefPubMed
• 35.P. Ameri, A. Giusti, M. Boschetti, G. Murialdo, F. Minuto, D. Ferone, Interactions between vitamin D and IGF-I: from physiology to clinical practice. Clin. Endocrinol. (Oxf) 79, 457–463 (2013)CrossRef
• 36.A. Ajmal, A. Haghshenas, S. Attarian, M. Barake, N.A. Tritos, A. Klibanski, K.K. Miller, L.B. Nachtigall, The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly. Pituitary 17, 366–373 (2014)CrossRefPubMed

---

See also web

• Wikipedia
  "In over 90 percent of acromegaly patients, the overproduction of growth hormones is caused by a benign tumor of the pituitary gland, called an adenoma. "

This page was renamed Feb 2019.
There have actually been 20931 visitors to this page since it was originally made